Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Researchers study worldwide use of Hib vaccine; Neighbors' decisions influence adoption of vaccines

Researchers at the Johns Hopkins Bloomberg School of Public Health conducted an analysis of worldwide use of Haemophilus influenza Type b vaccine (Hib) to determine what factors influenced a nation's adoption of the vaccine.

16 Mar 2010

Opinions: Discrimination against sexual orientation; WFP in Somalia; Haiti's recovery; WHO's policy role

In a Washington Post opinion piece, Desmond Tutu, archbishop emeritus of Cape Town, South Africa, and Nobel Peace Prize recipient, speaks out against efforts to deny individuals "their fundamental rights and freedoms" based on their sexual orientation.

16 Mar 2010

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that data from a phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were published in The Lancet. This study met its primary endpoint, resulting in an average LDL-C reduction of greater than 100 mg/dL in this very high-risk patient population.

16 Mar 2010

GAVI calls meeting with existing, potential donors

The GAVI Alliance has "asked existing and potential donors to a meeting in The Hague on March 25 and 26 to challenge them to 'make a strong impact' on childhood death rates," Reuters reports. "GAVI, which is supported by the World Health Organization, the World Bank, UNICEF, the Bill & Melinda Gates Foundation and vaccine makers, says it has 40 percent of the $7 billion it needs between now and 2015 to help" immunize of millions of children in developing countries by 2015, according to the news service.

16 Mar 2010

TCAD therapy superior to double combinations and monotherapy against influenza viruses

Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy against multiple strains of pandemic and avian influenza viruses. Results of these studies were presented Sunday evening in an oral session at the XII International Symposium on Respiratory Viral Infections being held in Taipei.

15 Mar 2010

Today's Opinions and Editorials

After a year of national debate, a handful of House Democrats who oppose abortion may be the ones to decide whether health care reform goes forward or not. ... We are puzzled and dismayed that these legislators are willing to waste that opportunity because they say the onerous anti-abortion provisions in the Senate's bill are still not onerous enough (3/14).

15 Mar 2010

Hemispherx Biopharma reports net loss of $13,438,000 for fiscal year 2009

Hemispherx Biopharma, Inc., announced its financial results for the fiscal year ended December 31, 2009. The net loss for the year (including non-cash charges) was approximately $13,438,000 or $0.12 per share as compared to a net loss of $12,219,000 or $0.16 per share in 2008.

15 Mar 2010

More focus on reaching MDGs needed, development officials say

During a conference in London Thursday, development officials urged world leaders to "accelerate efforts to meet the Millennium Development Goals (MDGs) by 2015 and [said] rich countries must make good on promises to boost aid to poorer nations," Reuters AlertNet reports.

15 Mar 2010

Mitral regurgitation: MitraClip safe, effective alternative option to open heart surgery

NorthShore University HealthSystem (NorthShore) interventional cardiologist, Ted Feldman, MD, presented data today at the American College of Cardiology annual scientific sessions from the EVEREST II trial (Endovascular Valve Edge-to-Edge REpair STudy) demonstrating the MitraClip, a novel, first-in-class catheter-based device, is a safe and effective alternative to open heart surgery for select patients with mitral regurgitation.

15 Mar 2010

Immunizing children against seasonal influenza can protect unvaccinated community against influenza

Results of a clinical trial conducted in a largely self-contained religious community during the 2008-09 influenza season show that immunizing children against seasonal influenza can significantly protect unvaccinated community members against influenza as well. The study was conducted to determine if immunized children could act as a barrier to limit the spread of influenza to the wider, unvaccinated community, a concept known as herd immunity.

15 Mar 2010

GAVI Alliance reaches agreement with drugmakers on reduced-price pneumococcal vaccines

Several drugmakers have reached an agreement "to supply up to 200 million doses a year of cut-price pneumococcal vaccines to developing nations," according to GAVI Alliance, Reuters reports.

15 Mar 2010

ampliPHOX detection technology of InDevR in beta site-testing in anticipation of upcoming product launch

InDevR, developer of advanced life science products, announced that its ampliPHOX Colorimetric Detection Technology is being beta site-tested in anticipation of an upcoming product launch. The original intellectual property was licensed from the University of Colorado at Boulder.

12 Mar 2010

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability.

12 Mar 2010

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate).

12 Mar 2010

Flu infection during pregnancy may increase risk of schizophrenia in offspring

Rhesus monkey babies born to mothers who had the flu while pregnant had smaller brains and showed other brain changes similar to those observed in human patients with schizophrenia, a study at the University of Wisconsin-Madison in collaboration with the University of North Carolina at Chapel Hill has found.

12 Mar 2010

Children with chronic illness more likely to develop H1N1 influenza: Study

As critical care professionals develop a better understanding of the progression of H1N1, they are becoming better prepared to treat children with severe cases, according to a new study that will be published in the March issue of Pediatric Critical Care Medicine (PCCM).

12 Mar 2010

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells.

12 Mar 2010

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Baxter International Inc., in conjunction with DynPort Vaccine Company LLC, a CSC Company, today presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives. The data were presented at the International Congress on Infectious Disease (ICID) in Miami, Florida.

From Baxter International Inc. 12 Mar 2010

WHO welcomes Gates Foundation support in advancing global vaccine efforts

WHO welcomes the Bill & Melinda Gates Foundation pledge of US$ 10 billion over the next ten years to accelerate global vaccine efforts.

12 Mar 2010

HTDS receives Registration Certificate for MEVAC-Vari vaccine in Guatemala

Hard to Treat Diseases and its subsidiary Mellow Hope announce that the company received Registration Certificate for its MEVAC-Vari vaccine in Guatemala.

12 Mar 2010

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Researchers study worldwide use of Hib vaccine; Neighbors' decisions influence adoption of vaccines

Opinions: Discrimination against sexual orientation; WFP in Somalia; Haiti's recovery; WHO's policy role

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

GAVI calls meeting with existing, potential donors

TCAD therapy superior to double combinations and monotherapy against influenza viruses

Today's Opinions and Editorials

Hemispherx Biopharma reports net loss of $13,438,000 for fiscal year 2009

More focus on reaching MDGs needed, development officials say

Mitral regurgitation: MitraClip safe, effective alternative option to open heart surgery

Immunizing children against seasonal influenza can protect unvaccinated community against influenza

GAVI Alliance reaches agreement with drugmakers on reduced-price pneumococcal vaccines

ampliPHOX detection technology of InDevR in beta site-testing in anticipation of upcoming product launch

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

Flu infection during pregnancy may increase risk of schizophrenia in offspring

Children with chronic illness more likely to develop H1N1 influenza: Study

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

WHO welcomes Gates Foundation support in advancing global vaccine efforts

HTDS receives Registration Certificate for MEVAC-Vari vaccine in Guatemala

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in